Rapport Therapeutics, Inc (RAPP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Rapport Therapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Rapport Therapeutics, Inc (RAPP) has returned 3.13% so far this year and 211.96% over the past 12 months.

Based on dividend-adjusted daily data since Jun 7, 2024, RAPP's average daily return is +0.36%, while the average monthly return is +4.17%. At this rate, your investment would double in approximately 1.4 years.

Historically, 50% of months were positive and 50% were negative. The best month was Sep 2025 with a return of +68.5%, while the worst month was Feb 2025 at -38.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, RAPP closed higher 50% of trading days. The best single day was Sep 8, 2025 with a return of +119.2%, while the worst single day was Mar 3, 2025 at -28.7%.

Rapport Therapeutics, Inc has an annualized alpha of 106.90%, beta of 1.41, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 10, 2024.

• This stock captured 198.02% of S&P 500 Index gains and 133.06% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RAPP ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Rapport Therapeutics, Inc (RAPP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Rapport Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rapport Therapeutics, Inc was 75.54%, occurring on Mar 3, 2025. Recovery took 130 trading sessions.

The current Rapport Therapeutics, Inc drawdown is 1.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Rapport Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Rapport Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.